Drug Trial Radar · NCT07789899
A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Two GSK3862995B Formulations in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Aug 18, 2026
Primary completion
Sep 7, 2027
Study completion Sep 7, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Aug 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will compare two formulations of the investigational medicine GSK3862995B in healthy adults. The study aims to assess how the body absorbs and processes the medicine, and to evaluate its safety and tolerability.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
GSK3862995BDrug
GSK3862995B will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Serum Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-t)] of GSK3862995BTime frame: From pre-dose on Day 1 through Week 36
- Maximum Observed Serum Concentration (Cmax) of GSK3862995BTime frame: From pre-dose on Day 1 through Week 36
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to Week 49
- Number of Participants With Clinically Significant Changes in Laboratory Parameters, Vital Signs, and 12-Lead Electrocardiogram (ECG) FindingsTime frame: Up to Week 36
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Cambridge, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.